Catalyst Biosciences Sells Complement Portfolio for $60 Million
23. Mai 2022 08:30 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex...
Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results
09. Mai 2022 08:30 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31,...
Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update
31. März 2022 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and year ended...
Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO’s Complement Portfolio in Ophthalmology
15. März 2022 17:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for...
Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives
17. Februar 2022 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it has retained Perella Weinberg Partners (PWP) as a financial advisor to...
Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency
25. Januar 2022 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric...
Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
22. November 2021 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside...
Catalyst Biosciences Announces Change in Corporate Strategy
12. November 2021 07:00 ET
|
Catalyst Biosciences, Inc.
Company to discontinue MarzAA development; focus on developing its complement portfolio Management to host a call today at 8:30 am ET SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) --...
Catalyst Biosciences Announces CFI Variant Presentations at Two Upcoming Scientific Conferences
29. Oktober 2021 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Grant Blouse, Ph.D., chief scientific officer, will present at two...
Catalyst Biosciences Announces Chief Financial Officer Transition
13. Oktober 2021 16:05 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that its chief financial officer, Clinton Musil, has resigned for personal...